B of A Securities Maintains Underperform on United Therapeutics, Lowers Price Target to $280
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Greg Harrison maintains an Underperform rating on United Therapeutics (NASDAQ:UTHR) and lowers the price target from $303 to $280.
August 01, 2024 | 11:28 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B of A Securities analyst Greg Harrison maintains an Underperform rating on United Therapeutics and lowers the price target from $303 to $280.
The Underperform rating and lowered price target from a major analyst firm like B of A Securities is likely to negatively impact investor sentiment and short-term stock price of United Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100